tiprankstipranks
Trending News
More News >
Wuxi Biologics (Cayman) (WXIBF)
:WXIBF
US Market

Wuxi Biologics (Cayman) (WXIBF) Income Statement

Compare
128 Followers

Wuxi Biologics (Cayman) Income Statement

Last quarter (Q2 2024), Wuxi Biologics (Cayman)'s total revenue was ¥8.57B, an increase of 18.98% from the same quarter last year. In Q2, Wuxi Biologics (Cayman)'s net income was ¥1.50B. See Wuxi Biologics (Cayman)’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
¥ 18.68B¥ 17.03B¥ 15.27B¥ 10.29B¥ 5.61B
Gross Profit
¥ 7.65B¥ 6.83B¥ 6.72B¥ 4.83B¥ 2.53B
Operating Expenses
¥ 2.68B¥ 2.88B¥ 1.93B¥ 1.36B¥ 771.43M
Depreciation and Amortization
¥ 1.44B¥ 1.17B¥ 800.67M¥ 481.78M¥ 303.01M
EBITDA
¥ 6.43B¥ 5.50B¥ 6.22B¥ 4.51B¥ 2.31B
Operating Income
¥ 4.97B¥ 3.95B¥ 6.16B¥ 3.86B¥ 1.76B
Other Income/Expenses
¥ -139.41M¥ 224.34M¥ 1.02B¥ 805.01M¥ 463.73M
Pretax Income
¥ 4.83B¥ 4.17B¥ 5.36B¥ 3.99B¥ 1.97B
Net Income
¥ 3.36B¥ 3.40B¥ 4.42B¥ 3.39B¥ 1.69B
Per Share Metrics
Basic EPS
¥ 0.89¥ 0.82¥ 1.06¥ 0.81¥ 0.43
Diluted EPS
¥ 0.85¥ 0.77¥ 1.01¥ 0.77¥ 0.40
Weighted Average Shares Outstanding
4.08B 4.16B 4.17B 4.40B 4.21B
Weighted Average Shares Outstanding (Diluted)
4.23B 4.35B 4.38B 4.42B 4.21B
Currency in CNY

Wuxi Biologics (Cayman) Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis